A study of tislelizumab with chemo and all trans retinoic acid for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (tislelizumab and all trans retinoic acid) plus standard chemotherapy for people with advanced esophageal squamous cell cancer that cannot be removed by surgery. The goal is to see if this new mix helps control the disease better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of esophageal cancer called squamous cell carcinoma that has spread or cannot be removed with surgery.
- You must not have had any previous treatment for advanced esophageal cancer, though if you had chemo or radiation more than 6 months ago and the cancer came back, you may still qualify.
- You must be at least 18 years old and have an ECOG performance status of 0 or 1 (meaning you are fully active or only limited in strenuous activity).
- You must not have active autoimmune diseases, HIV, uncontrolled hepatitis B or C, or other serious medical conditions like recent heart problems.
- Women who can become pregnant and men with partners who can become pregnant must use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
This trial tests a combination of the immunotherapy drug tislelizumab and the chemotherapy drug S-1 for people with a specific type of esophageal cancer that still has some cancer cells in the main tumor but no cancer in lymph nodes after surgery. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes at the time of surgery.
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.